SERTRALINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for sertraline hydrochloride and what is the scope of freedom to operate?

Sertraline hydrochloride is the generic ingredient in two branded drugs marketed by Almatica, Appco, Novitium Pharma, Skg Pharma, Umedica, Zenara, Zydus Lifesciences, Aurobindo Pharma, Ranbaxy Labs Ltd, Strides Pharma, Viatris, Accord Hlthcare, Ascent Pharms Inc, Chartwell Molecular, Granules, Heritage, Heritage Pharma Avet, Hikma Pharms, Invagen Pharms, Ivax Sub Teva Pharms, Lupin, Mylan Pharms Inc, Oxford Pharms, Pharmaco, Pharmobedient, Quagen, Reyoung, Sciegen Pharms, Sun Pharm Inds (in), Sun Pharm Inds Ltd, Torrent Pharms, Tp Anda Holdings, and Zydus, and is included in thirty-nine NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for sertraline hydrochloride. Fifty-one suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for SERTRALINE HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	33
NDAs:	39
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	51
Raw Ingredient (Bulk) Api Vendors:	147
Clinical Trials:	340
What excipients (inactive ingredients) are in SERTRALINE HYDROCHLORIDE?	SERTRALINE HYDROCHLORIDE excipients list
DailyMed Link:	SERTRALINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for SERTRALINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stanford University	PHASE2
Lakshmi N Yatham	PHASE3
South Valley University	NA

See all SERTRALINE HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for SERTRALINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 100MG BASE	TABLET;ORAL
		EQ 50MG BASE	TABLET;ORAL
		EQ 25MG BASE	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for SERTRALINE HYDROCHLORIDE

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Cytochrome P450 2D6 Inhibitors Serotonin Uptake Inhibitors

Medical Subject Heading (MeSH) Categories for SERTRALINE HYDROCHLORIDE

Antidepressive Agents

Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for SERTRALINE HYDROCHLORIDE

N06AB	Selective serotonin reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for SERTRALINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOLOFT	Tablets	sertraline hydrochloride	150 mg and 200 mg	019839	1	2005-11-09
ZOLOFT	Oral Concentrate	sertraline hydrochloride	20 mg/mL	020990	1	2003-12-09

US Patents and Regulatory Information for SERTRALINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heritage Pharma Avet	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	TABLET;ORAL	077663-002	Feb 6, 2007		DISCN	No	No
Accord Hlthcare	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	TABLET;ORAL	202825-003	Nov 7, 2014	AB	RX	No	No
Zydus	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	TABLET;ORAL	077106-003	Feb 6, 2007		DISCN	No	No
Lupin	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	TABLET;ORAL	077670-001	Feb 6, 2007	AB	RX	No	No

Expired US Patents for SERTRALINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-001	Dec 30, 1991	5,744,501
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-003	Dec 30, 1991	4,536,518*PED
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-005	Mar 6, 1996	5,789,449
Viatris	ZOLOFT	sertraline hydrochloride	CONCENTRATE;ORAL	020990-001	Dec 7, 1999	4,536,518*PED

Sertraline Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Sertraline hydrochloride, a selective serotonin reuptake inhibitor (SSRI), has maintained a significant position in the antidepressant and anxiolytic markets for decades. Its patent expiry in 2000 opened the door for widespread generic competition, fundamentally altering its market dynamics and financial trajectory from a blockbuster innovator drug to a mature, high-volume generic. The market is now characterized by intense price competition among numerous generic manufacturers, with sales driven by volume and cost-effectiveness rather than novel intellectual property.

What is the Historical Patent Landscape of Sertraline Hydrochloride?

The original patent for sertraline hydrochloride was filed by Pfizer Inc. and subsequently granted, protecting its market exclusivity for a defined period.

• Original Patent Grant: The core composition of matter patent for sertraline was granted in the United States on April 11, 1989.
• Exclusivity Period: This patent provided market exclusivity until its expiration.
• Patent Expiry Date: The primary U.S. patent for sertraline hydrochloride expired in 2000.
• Generic Entry: Following patent expiry, numerous pharmaceutical companies were able to introduce generic versions of sertraline.
• Subsequent Patents: While the main composition of matter patent expired, secondary patents related to specific formulations, manufacturing processes, or new indications might have existed. However, these did not extend the primary market exclusivity for the active pharmaceutical ingredient (API) itself.
• Litigation: As is common with blockbuster drugs, there were patent challenges and litigation surrounding sertraline, particularly concerning extensions and generic challenges. For instance, in the late 1990s, generic manufacturers sought to invalidate or circumvent Pfizer's patents to gain earlier market entry.

What are the Current Market Dynamics for Sertraline Hydrochloride?

The market for sertraline hydrochloride is a mature, highly competitive generic landscape. Key characteristics include intense price pressure, high volume sales, and a consolidated manufacturing base.

• Generic Dominance: Sertraline hydrochloride is overwhelmingly sold as a generic medication. The brand name Zoloft, formerly a significant revenue generator for Pfizer, now holds a minimal market share.
• Price Erosion: The presence of multiple generic manufacturers has led to significant price erosion. The cost per milligram of sertraline is substantially lower compared to its innovator period.
• Market Volume: Despite price reductions, the overall market volume for sertraline remains substantial due to its widespread use in treating depression, anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).
• Key Players: Major players in the sertraline hydrochloride API and finished dosage form market include generic pharmaceutical manufacturers and contract manufacturing organizations (CMOs). Examples of companies that have historically manufactured or distributed sertraline include Teva Pharmaceutical Industries, Mylan N.V. (now Viatris), Sun Pharmaceutical Industries, Aurobindo Pharma, and numerous others globally.
• Supply Chain: The supply chain is global, with API manufacturing often concentrated in countries with lower production costs, such as India and China. Finished dosage forms are then manufactured and distributed worldwide.
• Regulatory Environment: Sertraline is approved by major regulatory bodies globally, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its generic status means that new drug applications (NDAs) are replaced by abbreviated new drug applications (ANDAs) in the U.S., requiring demonstration of bioequivalence.
• Competition Intensity: The competitive landscape is characterized by a large number of approved ANDAs, leading to a fragmented market among generic producers. This fragmentation further intensifies price competition.
• Therapeutic Class: As an SSRI, sertraline competes with other SSRIs (e.g., fluoxetine, escitalopram, citalopram), serotonin-norepinephrine reuptake inhibitors (SNRIs) (e.g., venlafaxine, duloxetine), and other classes of antidepressants and anxiolytics. However, its established efficacy, safety profile, and low cost ensure continued demand.

What is the Financial Trajectory of Sertraline Hydrochloride?

The financial trajectory of sertraline hydrochloride has transitioned from a high-revenue innovator drug to a high-volume, lower-margin generic.

• Innovator Peak Sales (Zoloft): During its period of market exclusivity, Zoloft (sertraline) was a blockbuster drug for Pfizer, generating billions in annual revenue. For example, in 1999, Zoloft sales were approximately $2.8 billion globally [1].
• Post-Patent Expiry Revenue Decline: Following the patent expiry in 2000, Zoloft's revenue declined sharply as generic competition entered the market.
• Generic Market Size: The U.S. generic sertraline market alone is valued in the hundreds of millions of dollars annually, driven by prescription volume. For instance, in 2022, U.S. retail sales of generic sertraline tablets exceeded $350 million [2].
• Global Generic Sales: Globally, the generic sertraline market is significantly larger. Precise figures are difficult to isolate for a single generic drug across all markets but are estimated to be in the billions of dollars in combined sales revenue for all manufacturers.
• Profit Margins: For generic manufacturers, profit margins on sertraline are considerably lower than innovator margins. These margins are heavily influenced by manufacturing efficiency, raw material costs, and competitive bidding in tender processes.
• Volume-Driven Business: The financial success of generic sertraline is primarily driven by high sales volumes. Manufacturers compete on cost and the ability to supply large quantities reliably.
• API Manufacturing Economics: The economics of sertraline API manufacturing are critical. Companies with optimized synthesis routes and economies of scale in API production have a competitive advantage.
• Contract Manufacturing: Many pharmaceutical companies rely on CMOs for both API synthesis and finished dosage form manufacturing, further commoditizing production.
• Market Maturity: The financial trajectory is stable in terms of demand but declining in terms of revenue per unit. Growth is primarily linked to population growth, increased diagnosis rates for mental health conditions, and market penetration in developing economies, rather than new product development or expanded indications.

What are the Key Therapeutic Indications and Market Positioning?

Sertraline hydrochloride is established for a range of psychiatric conditions, positioning it as a first-line treatment option due to its efficacy and cost-effectiveness.

• Major Depressive Disorder (MDD): This is one of the primary indications for sertraline, making it a widely prescribed antidepressant.
• Obsessive-Compulsive Disorder (OCD): Sertraline is effective in reducing the symptoms of OCD in both adults and children.
• Panic Disorder: It is used to treat panic disorder, characterized by recurrent, unexpected panic attacks.
• Social Anxiety Disorder (Social Phobia): Sertraline helps to manage the fear and avoidance of social situations.
• Post-Traumatic Stress Disorder (PTSD): The drug is indicated for the treatment of PTSD, including symptoms like intrusive memories, avoidance, and hyperarousal.
• Premenstrual Dysphoric Disorder (PMDD): Sertraline is also prescribed to alleviate the severe mood symptoms associated with PMDD.
• Market Positioning: Sertraline is positioned as a cost-effective, first-line therapy for its indicated conditions. Its long history of use, well-understood efficacy and safety profile, and availability as a low-cost generic make it a preferred choice for healthcare providers and payers, particularly in budget-constrained healthcare systems. It competes directly with other SSRIs and SNRIs, often differentiated by price and specific patient tolerability.

What are the Regulatory and Manufacturing Considerations?

Manufacturing and regulatory compliance are critical for generic sertraline producers to ensure product quality and market access.

• Abbreviated New Drug Application (ANDA): In the U.S., generic manufacturers must file an ANDA with the FDA, demonstrating bioequivalence to the reference listed drug (Zoloft).
• Good Manufacturing Practices (GMP): All manufacturing facilities producing sertraline API and finished dosage forms must adhere to strict GMP standards set by regulatory authorities like the FDA, EMA, and others.
• Quality Control: Rigorous quality control measures are in place for raw material testing, in-process controls, and finished product release to ensure identity, strength, quality, and purity.
• API Sourcing: Manufacturers must ensure a reliable and compliant supply of sertraline API. This often involves qualifying multiple suppliers and auditing their manufacturing processes and quality systems.
• Formulation Development: While the API is generic, variations in inactive ingredients and manufacturing processes can exist between different generic products, requiring careful bioequivalence studies.
• Inspection and Audits: Manufacturing sites are subject to regular inspections by regulatory agencies and customer audits to verify compliance with GMP and other regulations.
• Intellectual Property (IP) Landscape (Post-Patent Expiry): While primary patents have expired, manufacturers must navigate any remaining secondary patents related to specific polymorphic forms, manufacturing processes, or drug delivery systems to avoid infringement.
• Supply Chain Security: Ensuring the integrity and security of the supply chain from API to finished product is paramount to prevent counterfeiting and ensure patient safety.

Key Takeaways

• Sertraline hydrochloride transitioned from an innovator blockbuster to a mature, high-volume generic following its U.S. patent expiry in 2000.
• The market is characterized by intense price competition among numerous generic manufacturers, with sales driven by volume.
• Global generic sales represent billions of dollars annually, though profit margins per unit are low.
• Key therapeutic indications include MDD, OCD, panic disorder, social anxiety disorder, PTSD, and PMDD, positioning it as a cost-effective first-line treatment.
• Manufacturing and regulatory compliance, including adherence to GMP and successful ANDA filings, are critical for market participation.

Frequently Asked Questions

1. What was the approximate peak annual revenue for Zoloft (sertraline hydrochloride) during its patent exclusivity?

Zoloft achieved peak annual global sales of approximately $2.8 billion in 1999.

2. How has the price of sertraline hydrochloride changed since its patent expiry?

The price has significantly eroded due to generic competition, with the cost per milligram substantially lower than during the innovator period.

3. What is the primary driver of sales for generic sertraline hydrochloride today?

Sales are driven by high prescription volumes rather than novel intellectual property or premium pricing.

4. Which regions are major hubs for sertraline hydrochloride API manufacturing?

Major API manufacturing is concentrated in countries with lower production costs, notably India and China.

5. What regulatory hurdles must generic sertraline manufacturers clear in the U.S. market?

Manufacturers must obtain FDA approval via an Abbreviated New Drug Application (ANDA), demonstrating bioequivalence to the reference listed drug.

Citations

[1] Pfizer Inc. (1999). Annual Report 1999.

[2] IQVIA National Sales Perspectives (NSP), U.S. Retail Prescription Data for Sertraline Tablets, Generic. (2022).